Key facts
- It has raised $21.5M; the latest was Later Stage VC ($21.5M) in Feb 2026.
- Notable investors include Co-Win Ventures, Bayland Capital, Hongfeng Capital, Jiangsu Winfast Investment, Ming Bioventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Med-Immune Science
- ·The full record, as it builds
Funding rounds
No funding rounds for Med-Immune Science are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Med-Immune Science
Manufacturer of biopharmaceutical drugs intended to advance the development of macromolecular therapies for cancer and immune-related disorders. The company offers antibody discovery platforms and macrophage target validation technologies, enabling medical researchers and oncology specialists to accelerate therapeutic innovation and enhance patient care.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2019
- Employees
- 32
- Website
- medimscience.com/
- Ownership
- Privately Held (backing)
Med-Immune Science doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Med-Immune Science shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Med-Immune Science in its N-PORT filings yet. We sweep new filings monthly.